spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  mTOR pathway 

 HSMN NewsFeed - 3 Mar 2023
Aadi Bioscience Announces Leadership Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Feb 2018
Kazia Receives FDA Orphan Designation for GDC-0084
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jun 2017
EUSA Pharma Receives Positive CHMP Opinion for Tivozanib for the First-Line Treatment of Advanced Renal Cell Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Dec 2015
Navitor Pharmaceuticals Announces $33 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Nov 2014
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2014
RestorGenex Appoints Mark Weinberg, MD, MBA Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2014
RestorGenex Announces Management Changes
Biopharmaceuticals Dermatology Ophthalmology Personnel
 HSMN NewsFeed - 19 Jun 2014
Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing for Novel Drug Discovery Targeting Cellular Nutrient Signaling to Treat Chronic Diseases and Rare Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 May 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2009
Intellikine Completes $51 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Jun 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
mTOR pathway
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.